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Cholesteryl ester transfer protein (CETP) inhibitors are 
currently being investigated because of their ability to 
increase high-density lipoprotein cholesterol levels. In 
various metabolic settings, the relationship between 
CETP and lipoprotein metabolism is complex and may 
depend largely on the concentration of triglyceride-
rich lipoproteins. Two CETP inhibitors, JTT-705 and 
torcetrapib, are in an advanced phase of development. 
Following hopeful intermediate results, a large endpoint 
study using torcetrapib has just been discontinued due 
to increased mortality in torcetrapib-treated subjects. In 
this review we summarize clinical data on the use of 
CETP inhibitors.
Introduction
Since reports in the late 1980s linking cholesteryl ester 
transfer protein (CETP) deficiency to high-density lipo-
protein cholesterol (HDL-C) elevation, strong interest in 
developing drugs that can inhibit CETP has arisen. At this 
moment, at least six CETP inhibitors are being evaluated 
[1], two of which have reached phase III clinical trials. 
The potency of CETP inhibition has been underscored by 
HDL-C increases of up to 100%, which clearly exceeds 
the efficacy of currently available HDL-C–raising thera-
pies. In comparison, nicotinic acid, which is at present the 
most powerful drug to increase HDL-C, can raise HDL-
C levels by 30% at most [2]. The unanswered question 
remains whether a pharmacologic increase in HDL-C will 
result in a decrease in coronary artery disease (CAD). In 
support of this idea, HDL-C has consistently been found 
to be inversely related to the risk of CAD in several large, 
prospective population studies. In fact, several studies 
support the effectiveness of nicotinic acid–associated 
HDL-C for reducing CAD. However, the atherogenic 
effects of CETP are still being debated. Very few studies 
have actually studied the relationship between CETP and 
CAD risk in humans. The first prospective study suggest-
ing a relationship between CETP deficiency and CAD was 
the Honolulu Heart Study, although these results were 
mitigated in a follow-up study [3]. In a large prospective 
study, CETP concentration was a positive determinant 
of CAD, but only in subjects with high triglycerides [4]. 
CETP concentration [5] and CETP activity [6] have also 
shown a positive correlation with increasing carotid 
intima media thickness as a surrogate endpoint for CAD. 
CETP regulates the exchange of cholesteryl esters 
(CE) and triglycerides (TG) between the apolipoprotein 
B (apoB)-containing lipoproteins and HDL in plasma. 
Accordingly, the role that CETP plays in atherosclerosis 
is complex and may depend on several factors, includ-
ing the plasma concentration of CETP, the plasma levels 
and composition (lipids and lipoproteins) of lipoprotein 
donors (HDL) as well as acceptors (apoB-containing 
lipoproteins), and  the overall metabolic condition [7]. 
Pharmacologic intervention may, therefore, be compli-
cated and depend on individual patient characteristics. 
At the present time, both the level of CETP inhibition 
and the required increase of HDL-C levels to prevent 
cardiovascular events in patients remain unknown. In 
this article we summarize data on CETP in various dys-
lipidemias. In addition, we address the impact of statins 
and fibrates on CETP activity and also outline ongoing 
clinical trials with CETP inhibitors as well as provide a 
summary of future trials.
CETP in Plasma and Lipid Metabolism 
CETP is a hydrophobic glycoprotein that is produced in 
the liver and adipose tissue. In the plasma compartment, 
the majority of CETP is bound to HDL, whereas only 1% 
of plasma CETP is present in free form [8]. The CETP 
concentration in healthy subjects varies between 1 and 
3 Ng/mL. In subjects with dyslipidemia, CETP concentra-
tion may increase up to two- to threefold [9••]. CETP 
promotes the transfer of CEs and triglycerides between 
HDL and apoB-containing plasma lipoproteins. HDL is the 
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primary lipoprotein particle on which CEs are generated by 
the reaction catalyzed by lecithin cholesterol acyltransferase 
(LCAT). TG, however, enter the plasma as a part of triglyc-
eride-rich lipoproteins (TRLs), which are chylomicrons, 
and as very low-density lipoproteins (VLDL). The overall 
effect of CETP is a net mass transfer of CE from HDL to 
TRLs in exchange for TG from TRLs to low-density lipo-
protein (LDL) and HDL [10]. The rate of this reaction is 
not only determined by the amount of CETP in plasma, 
but also by the concentration and composition of its CE 
donor (predominantly HDL) and acceptor (TRL) [11] 
CETP in Hypertriglyceridemia  
CETP activity is increased in hypertriglyceridemic 
patients [12] but not necessarily associated with an 
increase in CETP mass [13]. As a consequence of the 
high concentration of TRLs, the TG exchange surplus 
by CETP will start using LDL on top of HDL as a suit-
able CE donor. As a consequence, CETP activity results 
in a shift towards TG-enriched LDL and HDL particles, 
which both are substrates for hepatic lipase, leading to 
the formation of small, dense LDL particles [10] as well 
as smaller HDL particles [14]. The latter changes have 
been associated with a proatherogenic state. In fact, 
CETP has been shown to predict CAD predominantly in 
patients with high triglyceride levels [4]. These findings 
suggest that CETP inhibition may have beneficial effects 
in hypertriglyceridemic subjects, but this issue remains 
to be addressed.        
A common form of hyperlipidemia characterized by 
high TG levels and low HDL-C levels is familial com-
bined hyperlipidemia. This dyslipidemia is characterized 
by overproduction of VLDL with or without impaired 
clearance of TRLs [15]. Compared with normolipidemic 
individuals, patients with combined hyperlipidemia have 
an increased CETP activity [16], although this find-
ing has not been equivocal [17].  The combination of 
high triglycerides with low HDL theoretically provides 
an attractive option for CETP inhibition. However, it 
should be kept in mind that the impact of CETP inhibi-
tion in a situation of long residence time for TRLs needs 
further evaluation. Recent subanalyses from a trial using 
torcetrapib [18•] showed that monotherapy with this 
drug has no effect on triglycerides levels. Surprisingly, 
in subjects with increased baseline triglycerides, the 
favorable effect of torcetrapib on LDL-C disappeared 
altogether. Hence, the exact efficacy of CETP inhibi-
tion in familial combined hyperlipidemia needs further 
study. The Rating Atherosclerotic Disease change by 
Imaging with A New CETP inhibitor (RADIANCE) 
study is designed to test the effect of the CETP inhibi-
tor torcetrapib in patients with mixed hyperlipidemia 
(LDL-C > 160 mg/dL and triglycerides > 150 mg/dL). 
This study will provide further insight in the effect of 
CETP inhibition in hypertriglyceridemic states.
Metabolic Disorders and CETP
Adipose tissue is the second major source of CETP pro-
duction. As a consequence, plasma CETP concentration 
closely correlates with the amount of adipose tissue [19]. 
It has been shown that both CETP mass and activity are 
increased in obese subjects as compared with non-obese 
individuals [19]. Weight reduction has been shown to 
reduce CETP mass and activity in morbidly obese women 
[20]. Obesity, and especially abdominal obesity, is part of 
the metabolic syndrome (MS), a condition with increasing 
prevalence worldwide. MS, defined as abdominal obesity, 
hypertension, insulin resistance, and dyslipidemia, is char-
acterized by low HDL-C and high triglycerides. Plasma 
CETP levels were higher in individuals with MS compared 
with subjects without MS, but only in men [21]. In addition, 
plasma CETP levels increased with increasing number of 
components of MS and correlated negatively with LDL size 
[21]. In this metabolic setting with increased adipose tissue 
and increased CETP activity, CETP increases the exchange 
of TG from VLDL particles to HDL particles, which are 
cleared more quickly by the kidney, resulting in lower 
HDL-C levels. CETP may also accelerate the exchange of 
TG (for cholesterol) from VLDL to LDL particles, resulting 
in more triglyceride-rich LDL particles. 
Diabetes mellitus (DM) is a strong risk factor for the 
development of premature atherosclerosis. Patients with 
DM generally develop dyslipidemia that is characterized by 
low HDL-C and high TG levels, both risk factors for ath-
erosclerosis in DM [22]. Small, dense LDL and increased 
VLDL secretion are also recognized as key features of dia-
betic dyslipidemia. The level of CETP activity in diabetes 
yields conflicting results depending on how the measure-
ment was performed (eg, exogenous or endogenous) [22]. 
In type 2 DM, CETP activity was reported increased, 
not altered or reduced [9••]. Glycation of lipoproteins 
that accept CE from HDL has been reported to be respon-
sible for the increased plasma CETP activity in type 2 DM 
[23]. Together with the plasma TG concentration, plasma 
CETP activity is a determinant of small, dense LDL in 
type 2 DM [9••,24]. These diseases share an important 
common characteristic, specifically the atherogenic lipid 
profile, which includes the triad of low HDL-C, high TG, 
and increased small, dense LDL particles. In this context 
the results of RADIANCE II are of major importance 
because most of the disorders with low HDL-C share the 
same atherogenic profile. The success of this trial may 
extend the clinical use of CETP inhibitors in other dis-
eases that are characterized by low HDL-C and high TG, 
such as diabetes and MS. 
CETP and Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a hereditary disorder 
characterized by elevated levels of plasma LDL and prema-
ture cardiovascular disease (CVD). Whereas LDL-C is the 
primary therapy target, low HDL-C was found to constitute 
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an independent and strong risk factor for the development 
of CVD in FH patients [25]. Both plasma CETP concen-
tration [5,26] and CETP activity [26] were demonstrated 
to be increased in individuals with hypercholesterolemia, 
and these patients show increased transfer of CE from 
HDL to apoB-containing lipoproteins, specifically to dense 
LDL subfractions [9••]. Higher CETP concentration in 
FH is correlated with higher LDL-C and apoB levels, a 
higher number of LDL particles, and smaller LDL size [5]. 
Therefore, CETP appears to be proatherogenic in FH by 
increasing the cholesterol content in apoB-containing lipo-
proteins that are known to accumulate in these patients. At 
present it is unknown how FH patients respond to CETP 
inhibition. RADIANCE I is a study designed to assess the 
effects of the CETP inhibitor torcetrapib on atherosclerotic 
progression in patients with heterozygous FH. Results of 
this study are anticipated in 2007. 
Environmental and Lifestyle Factors 
Affecting CETP
Plasma CETP is affected by variety of metabolic condi-
tions that are in themselves associated with changes in 
CAD risk. It has been shown that alcohol intake and 
physical exercise are associated with decreased CETP 
concentration [27,28] and that smoking is associated with 
high CETP activity [29]. In postmenopausal women, the 
lipoprotein profile is shifted towards a more atherogenic 
profile that is improved by hormone replacement therapy 
[30]. Compared with premenopausal women, CETP activ-
ity in postmenopausal women is significantly increased 
[30].  However, hormone replacement therapy does not 
appear to affect either plasma CETP levels or activity in 
postmenopausal women [9••,30].
Pharmacologic Modulation of CETP 
in Humans
Trials examining the impact of statins on CETP
Statins have been proven to reduce the risk of cardio-
vascular events by lowering the plasma levels of total 
and LDL-C. Statins have also been shown to decrease 
CETP activity through lowering plasma CETP concen-
tration and by reducing the number of apoB-containing 
lipoprotein particles [9••]. In normolipidemic subjects, 
simvastatin has been shown to reduce CETP concen-
tration and activity after 6 weeks of treatment [31]. A 
dose-dependent decrease in CETP activity with simv-
astatin was observed in normotriglyceridemic subjects 
with premature CAD [32], although HDL-C remained 
unchanged. Atorvastatin has been shown to lower CETP 
activity in hypertriglyceridemic subjects [33] in a dose-
dependent fashion. In combined hyperlipidemic subjects 
[34] and in patients with types IIa and IIb primary 
hyperlipoproteinemia [35], atorvastatin also produced 
a significant decrease in CETP activity. Whereas in 
the latter study HDL-C levels were not changed, 
increases in paraoxonase activity were observed, sug-
gesting improvement of the anti-inflammatory capacity 
of HDL-C [35]. In FH, pravastatin decreases CETP 
activity without affecting plasma CETP concentration 
[36]. Pravastatin reduced the elevated flux of CE from 
HDL to apoB-containing lipoproteins in these subjects 
as a result of a reduction in the LDL particle accep-
tor concentration [36]. Finally, in patients with type 2 
diabetes mellitus, pravastatin demonstrated a decrease 
in CETP activity after 8 weeks of treatment [37]. In a 
study with pravastatin in CAD subjects, higher CETP 
concentration was associated with faster progression 
of coronary atherosclerosis after 2 years of treatment 
[38]. Similarly, subjects with the highest baseline CETP 
levels showed the highest improvement in lipoprotein 
profile and angiographic parameters after 2 years of 
treatment with pravastatin. In a prospective longitudi-
nal observational study with pravastatin, patients with 
high plasma CETP concentrations at baseline were 
associated with fewer cardiovascular events compared 
with low plasma CETP concentrations in CAD patients 
treated with pravastatin [39].
Trials examining the impact of fibrates on CETP
Fibrates are peroxisome proliferator–activated receptor 
B (PPARB) ligands of moderate binding affinity that 
increase HDL-C levels by up to 15% [2]. Fibrates are cur-
rently used in the treatment of hypertriglyceridemia in 
the presence or absence of low HDL-C. Fibrates decrease 
triglyceride-rich acceptor lipoproteins, which can be 
expected to contribute to reduced plasma CETP activity. 
However, the effect of fibrates on CETP activity is vari-
able. Some fibrates reduce both CETP concentration and 
mass, whereas CETP activity has also been reported to 
increase. In a study evaluating two fibrates (gemfibrozil 
and bezafibrate), plasma CETP concentration remained 
unaltered in patients with type IIb hypercholesterolemia 
[40]. Despite high CETP activity in this population, nei-
ther gemfibrozil nor bezafibrate had an effect on CETP 
activity, although the decrease compared with placebo 
was borderline significant for bezafibrate. It has been 
suggested that the effect of bezafibrate on CETP activ-
ity is mediated by the decrease and the compositional 
change of the TRLs, which are the acceptors for CEs 
from HDL [40]. Fenofibrate decreases CETP activity 
in subjects with combined hyperlipidemia [41] and in 
patients with MS [42]. Gemfibrozil also decreases CETP 
activity in type IIa hyperlipidemic patients [43] but not 
in normolipidemic subjects [44]. 
Trials with CETP inhibitors
Two pharmacologic small-molecule inhibitors of CETP, 
JTT-705 and torcetrapib, are in an advanced phase of 
investigation and have been shown to successfully raise 
HDL cholesterol in humans (Table 1).
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JTT-705
JTT-705 inhibits CETP activity by forming a disulfide 
bond that causes irreversible binding to the protein. In 
a randomized, double-blind, placebo-controlled trial of 
198 healthy individuals with mild dyslipidemia, JTT-705 
was evaluated at doses of 300, 600, and 900 mg/d for 
4 weeks [45]. In the highest dose, a decrease in CETP 
activity of 37% was measured concomitantly with a 
34% increase in HDL-C from baseline after 4 weeks of 
treatment. At this dose, LDL-C was decreased by 7% 
and levels of TG were unaffected. 
JTT-705 in combination with pravastatin has been 
investigated in a randomized, double-blind, placebo-con-
trolled trial conducted in 155 individuals with elevated 
LDL-C who were already taking 40 mg/d of pravastatin 
[46]. After 4 weeks, JTT-705, 600 mg/d plus pravastatin 
decreased CETP activity by 30% and increased HDL-
C by 28% from baseline, whereas LDL-C decreased by 
6% and TG by 8% from baseline. JTT-705, 300 mg plus 
pravastatin was about half as effective as the higher dose, 
decreasing CETP activity by approximately 16% and 
increasing HDL-C by approximately 13% [46]. This dose 
did not influence LDL or TG levels. The combination 
therapy of JTT-705 with pravastatin was well tolerated 
and did not induce significant adverse effects.
In a single-center, randomized, double-blind clinical 
trial in 19 patients with familial hypoalphalipoprotein-
emia, 4 weeks of treatment with 600 mg of JTT-705 was 
associated with a 24% decrease in CETP activity and a 
19% increase in HDL-C levels [47]. Furthermore, CETP 
inhibition in this study was associated with favorable 
effects on HDL and LDL subfractions, with a con-
comitant reduction of oxidized LDL autoantibodies and 
enhanced serum paraoxonase activity. Like JTT-705, 
JTT-302 is an orally administered CETP inhibitor and 
is currently undergoing phase I trials for the potential 
treatment of dyslipidemia. 
Torcetrapib
Torcetrapib is a potent and selective inhibitor of CETP. 
It enhances the association between CETP and HDL, 
forming a complex that inhibits the transfer of lipids 
between HDL and other lipoproteins. In the first study 
with torcetrapib, 40 healthy normolipidemic subjects 
were randomized to receive placebo or increasing doses 
of torcetrapib ranging from 10 to 240 mg/d for 14 days. 
Activity of CETP was reduced by 12% to 80%. The con-
centration of HDL-C increased by 16% to 91% and that 
of LDL-C decreased by 21% to 42% [48]. In a second 
study, 19 subjects with low HDL-C levels (< 38.7 mg/dL) 
were treated with torcetrapib at doses up to 120 mg twice 
daily [49]. Some subjects also received atorvastatin. Torce-
trapib (120 mg) increased HDL-C by 61% and 46% in the 
presence and absence of atorvastatin, respectively. In six 
subjects who received 120 mg twice daily for another 4 
weeks, torcetrapib increased HDL-C by 106%. Further-
more, a 17% reduction in LDL-C levels was observed in 
the atorvastatin group. Both LDL and HDL particle size 
increased with torcetrapib treatment.
Recently, the efficacy and safety of torcetrapib mono-
therapy in combination with atorvastatin was investigated 
in two studies with patients with below-average HDL-C 
levels (men < 44 mg/dL and women < 54 mg/dL). In the 
first study, 162 patients who did not receive lipid-lower-
ing therapy were randomized to receive increasing doses 
of torcetrapib (10–90 mg/d) [18•]. After 8 weeks of treat-
ment a dose-dependent increase in HDL-C levels was 
observed, with a maximum increase of 55% in the high-
est-dose group (90 mg/d). This increase was accompanied 
by a 23% increase in apoA-I levels and a shift to larger 
parts of both HDL and LDL particles. In the highest-dose 
group, LDL-C levels decreased by 17%; however, this 
LDL-C–lowering effect was completely lost in patients 
with high baseline TG levels, suggesting that CETP inhibi-
tion may be insufficient as a monotherapy in patients with 
high TG levels. It was suggested that in a situation of high 
TG, the combination of compositional changes in VLDL 
and CETP inhibition leads to accelerated conversion of 
VLDL to LDL via lipoprotein lipases, which may abolish 
the effect of torcetrapib on LDL-C levels. Although there 
were no serious adverse effects, significant blood pressure 
increases were noted in two of the 140 subjects.
In the second study, 174 subjects who were already 
taking 20 mg/d of atorvastatin were randomized to 
8 weeks of double-blind treatment with placebo or 
increasing doses of torcetrapib [50•]. In general, the 
changes in the levels of HDL-C, LDL-C, and their respec-
tive apolipoproteins and particle sizes in this study were 
similar to that in the monotherapy study. However, the 
percent increase from baseline in HDL-C was less marked 
in the atorvastatin/torcetrapib group compared with the 
monotherapy group. For example, 90 mg/d of torcetrapib 
caused a 55% increase in HDL-C levels in the monother-
apy study whereas the same dose yielded a 40% increase 
in the atorvastatin/torcetrapib group. This difference may 
lie in the fact that atorvastatin decreases CETP activity 
and in that way additional inhibition of CETP by torce-
trapib yields less HDL-C increase. There were significant 
decreases in LDL-C levels in the two highest groups (60 
and 90 mg/d) of 16% and 19%, respectively, and these 
effects were independent of baseline TG levels. Statin 
therapy may help in reducing accumulation of LDL-C 
in patients with hypertriglyceridemia by upregulation of 
LDL receptors.  In this study 2.9% of the subjects showed 
a significant increase in blood pressure levels. The poten-
tial clinical relevance of this adverse effect is currently 
being evaluated.        
CETP Inhibition and (Surrogate) Endpoints
The current CETP inhibitors JTT-705 and torcetrapib 
have proven to be efficacious in increasing HDL-C levels 
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both when used as monotherapy or in combination with 
statin therapy. Moreover, they increase the mean size 
of HDL and LDL particles, an effect on the lipid pro-
file which is similar with previous reports of large HDL 
particles in individuals with CETP deficiency. Recently, 
Matsuura et al. [51•] have shown that HDL from CETP-
deficient subjects shows enhanced ability to promote 
cholesterol efflux from macrophages, which is an impor-
tant step in the reverse cholesterol transport pathway. 
The key question is, however, whether these compounds 
will be able to reduce cardiovascular events. Two stud-
ies on surrogate and clinical endpoints are ongoing with 
torcetrapib. The Investigation of Lipid Level manage-
ment Using Coronary Ultrasound to Assess Reduction of 
Atherosclerosis by CETP Inhibition and HDL Elevation 
(ILLUSTRATE) study is evaluating changes in atheroma 
volume in coronary arteries using intravascular ultra-
sound. A total of 1191 patients with CHD have been 
randomized to treatment, with results expected in the 
first quarter of 2007. A large clinical endpoint study with 
torcetrapib, the Investigation of Lipid Level Manage-
ment to Understand Its Impact in Atherosclerotic Events 
(ILLUMINATE) study, has also been initiated. This 
study has randomized approximately 15,000 subjects 
with coronary heart disease or coronary heart disease–
risk equivalents to receive either torcetrapib/atorvastatin 
or atorvastatin alone. The primary endpoint is composite 
of death, nonfatal myocardial infarction, or stroke. The 
most recent development is the premature discontinua-
tion of this trial on December 2, 2006 due to increased 
mortality rate in the torcetrapib-treated subjects. Thus, 
the combination of atorvastatin plus torcetrapib was 
linked to a 60% higher mortality rate compared with 
atorvastatin alone (ie, 82 deaths in the torcetrapib/atorv-
astatin group versus 51 deaths in the atorvastatin group). 
Of note, at present it is unclear whether the increase in 
cardiovascular mortality only applies to the torcetrapib 
compound or to all CETP inhibitors. In support of the 
former, torcetrapib has been linked to onset of hyperten-
sion, whereas other CETP inhibitors do not show this 
particular side effect.   
Conclusions 
The relationship between CETP and lipoprotein metabo-
lism is complex and may differ in various metabolic 
settings. CETP inhibitors exert a wide array of benefi-
cial effects on the lipid profile, including an increase in 
HDL and a decrease in the number of small, dense LDL 
particles. Until recently, safety and efficacy data on 
CETP inhibitors were good. The premature cessation 
of the endpoint trial using CETP inhibitor torcetrapib 
(ILLUMINATE), showing higher mortality during active 
treatment, has further complicated the matter. Future 
research has to unravel whether this adverse effect is com-
pound specific (eg, due to hypertension) or whether it will 
prove to be a complication for all CETP inhibitors. 
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